Jon Stonehouse is Former President and Chief Executive Officer of BioCryst Pharmaceuticals Inc (BCRX). The company reported total compensation of $12,951,082 for fiscal year 2025.
| Salary | $728,466 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $11,132,458 |
| Non-equity incentive plan | $1,052,633 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $37,525 |
| Total | $12,951,082 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure BioCryst Pharmaceuticals Inc filed April 23, 2026, accession 0001628280-26-026822.
| Peer-group chief executive median | $9,029,861 |
|---|---|
| Difference from that median | $3,921,221 |
| Percentile within the disclosed peer group | 53rd |
| Peers with a disclosed figure | 17 |
Medians and percentiles are computed across the peer group BioCryst Pharmaceuticals Inc discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jon Stonehouse this page | Former President and Chief Executive Officer | $12,951,082 |
| Charles Gayer | President and Chief Executive Officer; Former Chief Commercial Officer | $9,627,868 |
| Babar Ghias | Chief Financial Officer | $6,748,152 |
| Alane Barnes | Chief Legal Officer and Corporate Secretary | $5,616,032 |
| Helen Thackray | Former Chief Research and Development Officer | $4,339,624 |
| Anthony Doyle | Former Chief Financial Officer and Treasurer | $2,141,135 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full BioCryst Pharmaceuticals Inc compensation brief.
Jon Stonehouse's compensation sits inside BioCryst Pharmaceuticals Inc's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.